These findings are particularly germane to the growing interest in the potential for weight loss driven by GLP-1 receptor and/or glucose-dependent insulinotropic polypeptide receptor agonism to limit obesity-driven tumor growth. This evidence concerns the gene GIPR and neoplasm.